Genmab A/S Genmab Announces Net Sales Of Darzalex(R) (daratumumab) For The Second Quarter Of 2022
19 July 2022 - 08:33PM
UK Regulatory
TIDMGEN
Company Announcement
-- Net sales of DARZALEX(R) in the second quarter of 2022 totaled USD 1,986
million
-- Genmab receives royalties on worldwide net sales from Janssen Biotech,
Inc. (Janssen)
COPENHAGEN, Denmark; July 19, 2022 --
https://www.globenewswire.com/Tracker?data=XH0_nxAcKkYA8y2mhZ0TTzwlHOUwqe2amktmuQALKZe9hGZo9WvLpw-EzfY7b1ewG1bTgb6Hmws_kHKKljNJuQ==
Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade
sales of DARZALEX(R) (daratumumab), including sales of the
subcutaneous (SC) formulation (daratumumab and hyaluronidase-fihj,
sold under the tradename DARZALEX FASPRO(R) in the U.S.), as
reported by Johnson & Johnson were USD 1,986 million in the
second quarter of 2022. Net trade sales were USD 1,021 million in
the U.S. and USD 965 million in the rest of the world. Genmab
receives royalties on the worldwide net sales of DARZALEX, both the
intravenous and SC formulations, under the exclusive worldwide
license to Janssen to develop, manufacture and commercialize
daratumumab.
About Genmab
Genmab is an international biotechnology company with a core
purpose to improve the lives of people with cancer. For more than
20 years, Genmab's vision to transform cancer treatment has driven
its passionate, innovative and collaborative teams to invent
next-generation antibody technology platforms and leverage
translational research and data sciences, fueling multiple
differentiated cancer treatments that make an impact on people's
lives. To develop and deliver novel therapies to patients, Genmab
has formed 20+ strategic partnerships with biotechnology and
pharmaceutical companies. Genmab's proprietary pipeline includes
bispecific T-cell engagers, next-generation immune checkpoint
modulators, effector function enhanced antibodies and antibody-drug
conjugates.
Genmab is headquartered in Copenhagen, Denmark with locations in
Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo,
Japan. For more information, please visit Genmab.com
https://www.globenewswire.com/Tracker?data=XH0_nxAcKkYA8y2mhZ0TT1N4MhfnVa7MxZ7dShvwwDSN4pSPiH-R5qLIOAnEaK8KX9bvMNsGjcehy9AC4xiPng==
and follow us on Twitter.com/Genmab
https://www.globenewswire.com/Tracker?data=cAf5Re6b2PvyvETHLEKwFfpVxolWmH7_QWm6LrbbHqnErqck2pwSVCXKWSESxhvNw787wkkpR6Fxw6j4QB8axWOeXgoyeAX7P6J93ccnpq0=
.
Contact:
Marisol Peron, Senior Vice President, Communications and
Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
https://www.globenewswire.com/Tracker?data=uL2_Aa92w4CKINDupKGWiUO16TtqhBqmKrJncC3qj0K3MGmygxhYyw7FlALXrs-52EgIs-ApYcfC2nQ0aeZB7A==
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
https://www.globenewswire.com/Tracker?data=_i1Ie4KX6hVGbbI6HIodMzSaQ-QXpyJG6Q15g4qbTCdIhrEnthib5UQcM_6eSbsplAABEuLWB2WheenX2l8O3A==
This Company Announcement contains forward looking statements.
The words "believe", "expect", "anticipate", "intend" and "plan"
and similar expressions identify forward looking statements. Actual
results or performance may differ materially from any future
results or performance expressed or implied by such statements. The
important factors that could cause our actual results or
performance to differ materially include, among others, risks
associated with pre-clinical and clinical development of products,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products or technologies obsolete, and other factors. For a further
discussion of these risks, please refer to the risk management
sections in Genmab's most recent financial reports, which are
available on
https://www.globenewswire.com/Tracker?data=tsq5vmWX0XZf9aGIFZj6zcPWrqD1HlGH8LncaFZqylgDFqU5RDT0RpmJ4DMmETmh2Je9Wz9YUAzour4cCzLZMQ==
www.genmab.com and the risk factors included in Genmab's most
recent Annual Report on Form 20-F and other filings with the U.S.
Securities and Exchange Commission (SEC), which are available at
https://www.globenewswire.com/Tracker?data=tsq5vmWX0XZf9aGIFZj6zamimqkTRTyc8ao7LqLXHtzudwpKSqnqWdi28BtPxtCx_XWWM5z63UgQ2XzpvzFkacpWNhdyUffhd5dLxRvu5gU=
www.sec.gov. Genmab does not undertake any obligation to update or
revise forward looking statements in this Company Announcement nor
to confirm such statements to reflect subsequent events or
circumstances after the date made or in relation to actual results,
unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks:
Genmab(R) ; the Y-shaped Genmab logo(R) ; Genmab in combination
with the Y-shaped Genmab logo(R) ; HuMax(R) ; DuoBody(R) ; DuoBody
in combination with the DuoBody logo(R) ; HexaBody(R) ; HexaBody in
combination with the HexaBody logo(R) ; DuoHexaBody(R) and
HexElect(R) .
Company Announcement no. 34
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark
Attachment
-- 180722_CA34_DARZALEX Q2 Sales
https://ml-eu.globenewswire.com/Resource/Download/7e5331df-0e2a-4b52-8a73-e10b9564f2e8
(END) Dow Jones Newswires
July 19, 2022 06:33 ET (10:33 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Genuit (LSE:GEN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Genuit (LSE:GEN)
Historical Stock Chart
From Mar 2023 to Mar 2024